Robinson Cano could have performed his final recreation within the main leagues. The New York Mets second baseman examined optimism for the performance-enhancing drug stanozolol. It is the second time Cano has failed a PED take a look at, which suggests he’ll be suspended for a complete season.
The optimistic take a look at additionally means Cano will forfeit the cash he is purported to earn subsequent 12 months. And that quantity is nothing to sneeze at – Cano will lose $24 million.
It is also fully potential he’ll by no means play in MLB once more. By the point this suspension ends, Cano might be 39 years previous. He’ll even have two optimistic drugs take a look at suspensions to his identity. He additionally examined optimism for a diuretic in 2018 whereas with the Seattle Mariners.
Will a group be prepared to take a danger on a participant within the twilight of his profession after they know the luggage that comes with him?
Cano was traded from the Mariners to the Mets in 2018. He had beforehand signed a 10-year, $240 million contracts with the Mariners. He nonetheless has two years and $48 million remaining on the deal, and the Mariners owe him $7.5 million.
The suspension additionally places a significant dent in Cano’s Corridor of Fame bid. Over 16 seasons, he is hit .303 with 2,624 hits, 334 homers, and 1,302 RBIs. He has additionally gained two Gold Glove awards. These are all high-quality numbers, notably for a second baseman. However, they might not be sufficient, particularly with two suspensions to his identity. Cano can have missed 242 video games in 4 years from suspension alone.
When Cano was suspended in 2018, he stated he obtained the diuretic from a licensed physician within the Dominican Republic. Cano started the drug, which was banned by MLB, was to deal with a medical ailment.
The new ownership team of the Mets should see what the remainder of their lineup can produce subsequent 12 months. At the least, they’ve loads of time to begin making ready.